Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.S. biotechs, which are independent but share founders and investors, raise a combined $94.5 million from the Russian sovereign fund and U.S. venture firms.

You may also be interested in...



Priming Russia’s Pharma Industry For Innovation

The Russian government’s aggressive plan to modernize the country’s pharmaceutical industry is stimulating entrepreneurial activities, as well as a flurry of deal activity between local and foreign companies. Many uncertainties remain about the potential opportunities, however, as foreign companies try to sort out changing regulatory and business dynamics.

Sanofi And Selecta To Partner On Immunotherapies For Life-Threatening Allergies

Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.

Russian Sovereign Fund Rusnano Invests $20 Million In CoDa Therapeutics

Wound healing company CoDa Therapeutics is the first Domain portfolio company to benefit from the venture capital firm’s new, $760 million partnership with Russian sovereign fund Rusnano.

Related Content

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel